Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Non-Current Debt: 2020-2025

Historic Non-Current Debt for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $51.6 million.

  • GeneDx Holdings' Non-Current Debt fell 0.87% to $51.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.6 million, marking a year-over-year decrease of 0.87%. This contributed to the annual value of $51.9 million for FY2024, which is 1.47% down from last year.
  • As of Q3 2025, GeneDx Holdings' Non-Current Debt stood at $51.6 million, which was down 0.20% from $51.7 million recorded in Q2 2025.
  • GeneDx Holdings' Non-Current Debt's 5-year high stood at $52.7 million during Q4 2023, with a 5-year trough of $6.1 million in Q3 2023.
  • Its 3-year average for Non-Current Debt is $39.5 million, with a median of $51.8 million in 2025.
  • As far as peak fluctuations go, GeneDx Holdings' Non-Current Debt tumbled by 43.18% in 2022, and later skyrocketed by 759.78% in 2024.
  • GeneDx Holdings' Non-Current Debt (Quarterly) stood at $11.0 million in 2021, then slumped by 43.18% to $6.2 million in 2022, then skyrocketed by 743.01% to $52.7 million in 2023, then declined by 1.47% to $51.9 million in 2024, then decreased by 0.87% to $51.6 million in 2025.
  • Its Non-Current Debt stands at $51.6 million for Q3 2025, versus $51.7 million for Q2 2025 and $51.8 million for Q1 2025.